ORIC Pharmaceuticals Announces Participation in Upcoming November 2026 Investor Conferences
ORIC Pharmaceuticals, Inc. announced that its management team will participate in three investor conferences throughout November 2026.
Stocks · News reference
ORIC Pharmaceuticals Announces Plans to Advance Enozertinib to Phase 3 Trial
ORIC Pharmaceuticals reported positive clinical data for enozertinib in first-line NSCLC patients with EGFR atypical mutations and announced plans to initiate a global Phase 3 trial.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Analysts Maintain Ratings and Price Targets for ORIC Pharmaceuticals
Several financial institutions reaffirmed their investment ratings and price targets for ORIC Pharmaceuticals on October 28, 2026.
H.C. Wainwright Maintains Buy Rating and $27 Price Target for ORIC Pharmaceuticals
H.C. Wainwright analyst Robert Burns has reiterated a Buy rating and a $27 price target for ORIC Pharmaceuticals.
Wedbush Maintains Outperform on ORIC Pharmaceuticals, Lowers Price Target to $14
Wedbush Adjusts Price Target on ORIC Pharmaceuticals to $14
Wedbush has revised its price target for ORIC Pharmaceuticals, lowering it from $17 to $14 while maintaining an Outperform rating.
Stifel Raises Price Target on ORIC Pharmaceuticals to $18
Stifel has increased its price target for ORIC Pharmaceuticals, Inc. from $14 to $18 per share.